HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China
| العنوان: | HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China |
|---|---|
| المؤلفون: | Yuhua Ruan, Zhongbao Zuo, Chang Song, Lingjie Liao, Miaomiao Li, Yi Feng, Chun-hua Liu, Shu Liang, Chao Zhou, Shujia Liang, Hui Xing, Min Chen, Lei Liu, Yiming Shao |
| المصدر: | Pathogens Volume 10 Issue 3 Pathogens, Vol 10, Iss 264, p 264 (2021) |
| بيانات النشر: | MDPI AG, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Microbiology (medical), medicine.medical_specialty, Efavirenz, Nevirapine, lcsh:Medicine, Drug resistance, Article, DNA sequencing, chemistry.chemical_compound, symbols.namesake, Interquartile range, Internal medicine, HIV drug resistance, medicine, Immunology and Allergy, interrupted antiretroviral therapy, sanger sequencing, Molecular Biology, Sanger sequencing, General Immunology and Microbiology, business.industry, lcsh:R, Antiretroviral therapy, Infectious Diseases, chemistry, symbols, next-generation sequencing, business, medicine.drug |
| الوصف: | Patients with antiretroviral therapy interruption have a high risk of virological failure when re-initiating antiretroviral therapy (ART), especially those with HIV drug resistance. Next-generation sequencing may provide close scrutiny on their minority drug resistance variant. A cross-sectional study was conducted in patients with ART interruption in five regions in China in 2016. Through Sanger and next-generation sequencing in parallel, HIV drug resistance was genotyped on their plasma samples. Rates of HIV drug resistance were compared by the McNemar tests. In total, 174 patients were included in this study, with a median 12 (interquartile range (IQR), 6–24) months of ART interruption. Most (86.2%) of them had received efavirenz (EFV)/nevirapine (NVP)-based first-line therapy for a median 16 (IQR, 7–26) months before ART interruption. Sixty-one (35.1%) patients had CRF07_BC HIV-1 strains, 58 (33.3%) CRF08_BC and 35 (20.1%) CRF01_AE. Thirty-four (19.5%) of the 174 patients were detected to harbor HIV drug-resistant variants on Sanger sequencing. Thirty-six (20.7%), 37 (21.3%), 42 (24.1%), 79 (45.4%) and 139 (79.9) patients were identified to have HIV drug resistance by next-generation sequencing at 20% (v.s. Sanger, p = 0.317), 10% (v.s. Sanger, p = 0.180), 5% (v.s. Sanger, p = 0.011), 2% (v.s. Sanger, p < 0.001) and 1% (v.s. Sanger, p < 0.001) of detection thresholds, respectively. K65R was the most common minority mutation, of 95.1% (58/61) and 93.1% (54/58) in CRF07_BC and CRF08_BC, respectively, when compared with 5.7% (2/35) in CRF01_AE (p < 0.001). In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at > 20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies. The prevalence of HIV drug resistance in ART interruption was higher than 15% in the survey. Next-generation sequencing was able to detect more minority drug resistance variants than Sanger. There was a sharp increase in minority drug resistance variants when the detection threshold was below 5%. |
| وصف الملف: | application/pdf |
| تدمد: | 2076-0817 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::176c6d3d758b5bf5b2d66eb57d61d7bfTest https://doi.org/10.3390/pathogens10030264Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....176c6d3d758b5bf5b2d66eb57d61d7bf |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20760817 |
|---|